Where Does Dynamic Value Assessment Fit Into Our Role as Agents Advising Our Patients With Cancer?

被引：1
|
作者：
Blayney, Douglas W. [1 ]
机构：
[1] Stanford Canc Inst, 875 Blake Wilbur Dr,CC2219, Stanford, CA 94305 USA
来源：
JOURNAL OF ONCOLOGY PRACTICE | 2016年 / 12卷 / 12期
关键词：
CLINICAL ONCOLOGY; AMERICAN SOCIETY;
D O I：
10.1200/JOP.2016.016022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1211 / 1213
页数：3
相关论文
共 50 条
  • [21] Does gender have any role in intravenous rtPA-treated patients? Our experience from the TCD multicenter study
    Al-Hussain, Fawaz
    Hussain, Muhammad S.
    Ibrahim, Mohamed M.
    Uchino, Ken
    Molina, Carlos
    Khurshid, Khan A.
    Salam, Abdul
    Shuaib, Ashfaq
    Demchuk, Alexandrov M.
    Alexandrov, Andrei V.
    Saqqur, Maher
    [J]. STROKE, 2007, 38 (02) : 500 - 500
  • [22] End-of-Life Care: Where Does the Standard Oncology Care Fail Our Patients and What Do We, as Oncologists, Need to Do Differently?
    Charalambous, Haris
    [J]. JAMA INTERNAL MEDICINE, 2013, 173 (06) : 474 - 475
  • [23] Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents
    C Le Tourneau
    V Servois
    V Diéras
    L Ollivier
    P Tresca
    X Paoletti
    [J]. British Journal of Cancer, 2012, 106 : 854 - 857
  • [24] Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents
    Le Tourneau, C.
    Servois, V.
    Dieras, V.
    Ollivier, L.
    Tresca, P.
    Paoletti, X.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (05) : 854 - 857
  • [25] ADVANCED OVARIAN CANCER: ARE WE UNDERSTAGING OUR PATIENTS? THE ROLE OF FDG-PET/CT BEFORE PRIMARY TREATMENT
    Glickman, A. G.
    Gil Ibanez, B.
    Paredes, P.
    Bunesch, L.
    Sebastia, M. C.
    Nicolas, I.
    Rodriguez-Trujillo, A.
    Munmany, M.
    Del Pino, M.
    Fuste, P.
    Pahisa, J.
    Torne, A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1507 - 1507
  • [26] ADVANCED OVARIAN CANCER: ARE WE UNDERSTAGING OUR PATIENTS? THE ROLE OF FDG-PET/CT BEFORE PRIMARY TREATMENT
    Glickman, A. G.
    Gil Ibanez, B.
    Paredes, P.
    Bunesch, L.
    Sebastia, M. C.
    Nicolas, I.
    Rodriguez-Trujillo, A.
    Munmany, M.
    Del Pino, M.
    Fuste, P.
    Pahisa, J.
    Torne, A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 290 - 290
  • [27] End-of-Life Care: Where Does the Standard Oncology Care Fail Our Patients and What Do We, as Oncologists, Need to Do Differently? Reply
    Prigerson, Holly G.
    Zhang, Baohui
    Nilsson, Matthew E.
    [J]. JAMA INTERNAL MEDICINE, 2013, 173 (06) : 475 - 475
  • [28] The value of 123I studies before radioiodine ablation or therapy in differentiated thyroid cancer patients. Our experience.
    Tardin, L.
    Parra, A.
    Andres, A.
    Santapau, A.
    Razola, P.
    Rambalde, E.
    Ayala, S.
    Prats, E.
    Banzo, J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S347 - S347
  • [29] Our experience of nursing/allied health practitioner led geriatric screening and assessment of older patients with cancer - a highly accessible model of care
    Thaker, Darshit Arunbhai
    McGuire, Peter
    Bryant, Geoffrey
    Wyld, David
    Leach, Justine
    Wheatley, Hermione
    Snape-Jenkinson, Stella
    Kelly, Bernadette
    Bourke, Anne
    Kennedy, Glen
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (08) : 1186 - 1192
  • [30] Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: Our first series of 100 patients
    Tanaka, Nobumichi
    Asakawa, Isao
    Kondo, Hideaki
    Tanaka, Motoyoshi
    Fujimoto, Kiyohide
    Hasegawa, Masatoshi
    Konishi, Noboru
    Hirao, Yoshihiko
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (01) : 70 - 74
12345